Cancer Metastasis: CKB suppresses epithelial-mesenchymal transition (EMT) in prostate cancer by inhibiting AKT activation . Downregulation of CKB correlates with poor prognosis in solid tumors .
Metabolic Regulation: In breast cancer, hypoxia-inducible factor (HIF)-dependent CKB expression promotes metastasis, while cyclocreatine therapy inhibits invasion .
Diagnostic Utility: Immunohistochemical staining using anti-CKB antibodies (e.g., ab108388) revealed significantly lower CKB levels in tumors vs. normal tissues (p < 0.001) .
4. Commercial Availability
Multiple vendors offer CKB antibodies with distinct properties:
Prostate Cancer: CKB sequesters AKT, blocking mTORC2-mediated activation and reducing metastasis . A C-terminal 84-amino-acid fragment of CKB is critical for this inhibition .
Breast Cancer: HIF-1α upregulates CKB under hypoxia, enhancing ATP production for invadopodia formation . Cyclocreatine, a CK inhibitor, reduces metastasis and synergizes with chemotherapy .
Neurological Disorders: CKB is highly expressed in brain tissue, with implications for neurodegenerative diseases .
CK-BB, also known as brain creatine kinase, is a cytoplasmic enzyme involved in energy metabolism. It is encoded by the CKB gene and is a member of the ATP:guanido phosphotransferase protein family. CK-BB acts as a homodimer in the brain and other tissues, and as a heterodimer with a similar muscle isozyme in the heart . The enzyme is crucial for maintaining energy homeostasis in cells with high and fluctuating energy demands, such as neurons .
Mouse anti-human CK-BB antibodies are monoclonal antibodies produced by immunizing mice with human CK-BB protein. These antibodies are highly specific and are used in various research applications, including Western blotting, immunohistochemistry, and ELISA. They are valuable tools for studying the expression and function of CK-BB in different tissues and under various physiological and pathological conditions .